Skip to main content

Advertisement

Table 2 Detailed characteristics of SLE patients included in this study

From: Increased interleukin-23 receptor+T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus

No. Patients Stage Treatments Doses (mg/d) SLEDAI score Clinical Features
1 inactive - - 4 PI
2 inactive PRD, AZT 5, 50 0 -
3 inactive PRD, AZT 35, 12.5 4 RA, MU
4 inactive PRD, AZT 5, 25 1 FE
5 inactive PRD N/A 5 RA, MU, FE
6 inactive PRD 2.5 0 -
7 inactive PRD, CPM 10, N/A 4 PU
8 inactive PRD 5 4 AR
9 inactive - - 4 PU
10 inactive PRD 5 0 -
11 inactive PRD, AZT 10, 50 4 PU
12 inactive PRD, CPM 7.5, 25 0 -
13 inactive PRD, CPM 10, 25 4 PU
14 inactive PRD 10 2 MU
15 inactive PRD, AZT 7.5, 100 5 PU, LP
16 inactive - - 0 -
17 active PRD, AZT 5, 100 8 HE, PU
18 active - - 8 HE, PU
19 active PRD, MMF 2.5, 2,000 8 HE, PU
20 active PRD 15 30 SZ, UC, HE, PU, PI, PE, LC, IDB
21 active PRD, AZT 5, 25 11 MY, HE, PL, LP
22 active PRD 5 8 AR, PU
23 active PRD, AZT 30, 50 29 VA, AR, HE, PU, PI, RA, MU, LP
24 active PRD 30 11 PU, AL, PL, FE, TC, LP
25 active PRD, AZT 5, 50 8 VA
26 active PRD, MMF 5, 500 13 HE, PU, AL, MU, LP
27 active PRD 20 12 HE, PU, PI
28 active PRD, AZT 20, 25 16 VA, PU, MU, LC
29 active PRD 15 6 PU, LC
  1. AL, alopecia; AR, arthritis; AZT, azathioprine; CPM, cyclophosphamide; FE, fever; HE, hematuria; IDB, Increased DNA binding; LC, low complement; LP, leucopenia; MMF, mycophenolate mofetil; MU, mucosal ulcers; MY, myositis; N/A, data not available; PE, pericarditis; PI, pyuria; PL, pleurisy; PRD, prednisolone; PU, proteinuria; RA, rash; SZ, seizure; TC, thrombocytopenia; UC, urinary casts; VA, vasculitis.